Wakefield Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Wakefield Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-20,874	Closed	-$575K	–	184
2023 Q3	$575K	Sell	20,874 -918	-4%	-$27.9K	0.26%	115
2023 Q2	$655K	Buy	+21,792	New	+$763K	0.26%	116
2022 Q1	–	Sell	-27,805	Closed	-$811K	–	197
2021 Q4	$811K	Buy	+27,805	New	+$844K	0.28%	116
2020 Q3	–	Sell	-21,831	Closed	-$518K	–	171
2020 Q2	$518K	Buy	+21,831	New	+$482K	0.25%	114

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wakefield Asset Management's SUPN Position: Q4 2023 in Review

Wakefield Asset Management sold out of Supernus Pharmaceuticals (SUPN) in Q4 2023, closing a stake of 20,874 shares — an estimated $575K sold.

Wakefield Asset Management first reported a position in SUPN in Q2 2020 and held it in 4 quarters. The position peaked at $811K in Q4 2021. 246 funds tracked by Wall St. Rank hold SUPN as of Q4 2023.

Wakefield Asset Management reported no remaining Supernus Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Wakefield Asset Management sold 20,874 Supernus Pharmaceuticals shares in Q4 2023, an estimated $575K.
Wakefield Asset Management first reported a position in Supernus Pharmaceuticals in Q2 2020 and held it in 4 quarters.
Wakefield Asset Management's Supernus Pharmaceuticals position peaked at $811K in Q4 2021.
246 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2023.

Based on Wakefield Asset Management's 13F filing for Q4 2023, filed 25 Jan 2024.